Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon &alpha;-2a on virological and serological responses in chronic hepatitis B patients

doi:10.3748/wjg.v22.i46.10210

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 46

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6816)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-6) series, Tables (1-3) series.

Item

Count

PDF

444

WORD

154

HTML

3707

Figures (1-6)

149

Tables (1-3)

130

Sum=4584

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

843

Download

1389

Sum=2232

Dec 14, 2016 (publication date) through Apr 30, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Gastroenterol. Dec 14, 2016; 22(46): 10210-10218
Published online Dec 14, 2016. doi: 10.3748/wjg.v22.i46.10210

Full Size Figure Download Figure

Figure 1 Trial design. HBV: Hepatitis B virus; CHB: Chronic hepatitis B; HBeAg: Hepatitis B envelope antigen; ULN: Upper limit of normal; ALT: Alanine aminotransferase; PegIFNα-2a: Pegylated interferon-α-2a; ETV: Entecavir; Qd: Quaque die; Po: Peros.

Citation: He LT, Ye XG, Zhou XY. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients. World J Gastroenterol 2016; 22(46): 10210-10218
URL: https://www.wjgnet.com/1007-9327/full/v22/i46/10210.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i46.10210